Corbus Pharmaceuticals Holdings (CRBP) Total Liabilities (2013 - 2025)

Corbus Pharmaceuticals Holdings has reported Total Liabilities for 13 years, with the latest figure at $20.7 million in Q4 2025.

• On a quarterly basis, Total Liabilities rose 53.83% year-over-year to $20.7 million in Q4 2025; TTM through Dec 2025 was $20.7 million, a 53.83% increase from a year earlier, with the FY2025 full-year figure at $20.7 million, up 53.83% from the prior year.
• Total Liabilities was $20.7 million for Q4 2025 at Corbus Pharmaceuticals Holdings, up from $17.4 million in the prior quarter.
• The five-year high for Total Liabilities was $48.6 million in Q1 2021, with the low at $12.8 million in Q1 2025.
• Average Total Liabilities over 5 years is $29.7 million, with a median of $33.0 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities tumbled 61.99% in 2024, then soared 53.83% in 2025.
• Over 5 years, Total Liabilities stood at $38.6 million in 2021, then fell by 13.72% to $33.3 million in 2022, then climbed by 5.57% to $35.2 million in 2023, then sank by 61.76% to $13.5 million in 2024, then surged by 53.83% to $20.7 million in 2025.
• The last three Total Liabilities figures came in at $20.7 million (Q4 2025), $17.4 million (Q3 2025), and $14.1 million (Q2 2025), per Business Quant data.